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Expression of major histocompatibility class II antigens on toms and prevents relapses [6]. Moreover, peripheral
polymorphonuclear neutrophils in patients with Wegener’s blood lymphocytes appear to be activated, as seen by
granulomatosis. increased expression of the interleukin 2 receptor
Background. Wegener’s granulomatosis is a systemic in-
(CD25), b1 integrin (CD29), and other adhesion mole-flammatory disease of unknown etiology. Many studies suggest
cules (ICAM-1 and LFA-3) [7–9]. Furthermore, an in-that autoimmune reactions are involved, and there is good evi-
dence for the participation of immunocompetent cells. In that creased proliferative response of patient-derived lym-
context, we examined the activation of polymorphonuclear neu- phocytes to proteinase 3 (PR3) or to polymorphonuclear
trophils (PMNs) of patients with Wegener’s granulomatosis. neutrophil (PMN) extracts, respectively, was described
Methods. In a prospective study, the expression on the sur-
recently [10–12]. Also, PMNs appear to be activated [13]face of PMNs of CD64 and of the major histocompatibility
as indicated by enhanced surface expression of lysosomalclass II (MHC II) antigen was measured by cytofluorometry
in whole blood. The expression of those antigens was correlated enzymes, particularly PR3 and elastase [14, 15].
to disease activity. In this prospective study, we analyzed PMNs of pa-
Results. Up to 15% of the peripheral PMNs of patients with tients suffering from Wegener’s granulomatosis with re-
active disease expressed MHC II. Follow-up studies showed
spect to the expression of activation markers, includingthat expression correlated closely with disease activity and that
the high-affinity receptor for IgG, CD64, and major his-it decreased rapidly under immunosuppressive therapy. Ex-
pression of CD64 was seen in approximately 50% of the pa- tocompatibility complex class II (MHC II) antigens
tients, regardless of disease activity. (HLA-DP, HLA-DQ, HLA-DR). Currently, PMNs are
Conclusion. MHC II expression on PMNs might serve as a considered to be end-stage–differentiated cells unable
novel diagnostic marker for active disease and appears to be
to synthesize and express MHC II. Only one report de-suitable for monitoring immunotherapy. Moreover, our data
scribes the induction on isolated human PMNs of MHCprovide evidence that PMNs, which are normally MHC II nega-
II expression in response to interferon g or colony-stimu-tive, acquire MHC II antigens in the course of disease and
may be an unrecognized function within the afferent limb of lating factor (GM-CSF) [16]. In our study MHC II ex-
the immune response. pression was found on the peripheral PMNs of patients
with active Wegener’s granulomatosis but not on PMNs
of patients with inactive disease.
Wegener’s granulomatosis is a systemic disease of un-
known etiology characterized by necrotizing granuloma,
METHODSvasculitis, and necrotizing glomerulonephritis [1–5]. There
is strong evidence for there to be an autoimmune process Patients
involved, as immunosuppressive therapy with cyclophos- After having obtained informed consent, patients with
phamide and corticosteroids efficiently relieves the symp- Wegener’s granulomatosis and other forms of vasculitis
attending the renal unit of the Heidelberg University
Hospital were included in a prospective study analyzingKey words: vasculitis, MHC class II antigen, PMN, inflammation, nec-
rotizing granuloma, T-cell activation. the expression of MHC II and of CD64 on PMNs of the
peripheral blood.Received for publication August 25, 1998
Wegener’s granulomatosis, microscopic polyangiitis,and in revised form December 18, 1998
Accepted for publication December 21, 1998 and Churg–Strauss syndrome were diagnosed according
to the definition of the Chapel Hill conference [17] and 1999 by the International Society of Nephrology
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to the American College of Rheumatology criteria [18]. (Hamburg, Germany). For comparison, isotype-matched
mouse IgGs (Dianova) were used in comparable proteinDisease activity was determined with the “Birmingham
vasculitis activity score” (BVAS) [19]. In all patients, anti- concentrations. To avoid changes in surface expression
caused by handling procedures, antibody labeling wasneutrophil cytoplasmic antibody (ANCA) titers, PR3
ANCA, and myeloperoxidase (MPO) ANCA were mea- performed in whole blood within two hours after with-
drawal as follows: to 100 ml whole blood, 5 ml of thesured as reported elsewhere [20, 21]. Laboratory tests
were performed by routine methods (Hitachi autoana- respective antibodies were given. After incubation for
30 minutes at room temperature, the erythrocytes werelyzer, blood cell counts by Coulter counter). Urine analy-
sis was done by test strips (Combur 8 kit; Boehringer lyzed by FACS lysing solution (Becton Dickinson,
Mountain View, CA, USA) and the residual cells wereMannheim, Mannheim, Germany), Addis Count, and
measurement of 24-hour protein excretion were done centrifuged and resuspended in phosphate-buffered sa-
line containing 1% bovine serum albumin (BSA) andwith Biuret, and urinary sediment was analyzed by phase
contrast microscopy. 0.1% sodium azide and 1% paraformaldehyde. Fluores-
cence was measured by FACSCalibur (Becton Dickin-Patients with vasculitis and additional complications,
including acute infections, as detected by x-ray, blood son) and was analyzed by CellQuest. Results are ex-
pressed as a percentage of gated cells in the respectivecultures, antiviral IgM titers, or measurement of procal-
citonin levels of more than 1 ng/ml [22], were excluded quadrant. CD64 expression on CD66b-positive PMNs
was measured with the same method. A monoclonalfrom the study, as were patients with chronic inflamma-
tory disease (cholecystolithiasis, inflammatory bowel dis- antibody to CD64 was obtained from Dianova.
ease, bronchitis, osteomyelitis), diabetes, or patients with
Determination of surface expression on T-cellskidney transplants.
The first patients entered the study in September 1996, The CD3, CD4/CD8 ratio, and expression of CD25 as
and the study was closed in April 1998. A number of activation marker on T cells were measured by cytofluo-
patients were seen repeatedly, usually in 8- to 10-week rometry using the respective antibodies in a Simultest
intervals or when the disease became active again or kit (all obtained from Becton Dickinson).
complications arose. According to the first clinical pre-
Statistical analysissentation, three groups of patients were formed: (a) pa-
tients with active disease (BVAS of more than 1), (b) The results for MHC II and CD64 for the three groups
patients with inactive disease (BVAS 1 or 0) under im- of patients and for the healthy donors as the fourth group
munosuppressive therapy, and (c) patients with inactive are presented as median with first and third quartiles.
disease and no therapy. Nonparametric tests (Kruskall–Wallis test and Wilcoxon
Patients with systemic bacterial infections. Twenty- test) were used to compare the results. As pair-wise com-
four patients with systemic bacterial infections were in- parisons were intended, a closure testing procedure was
cluded in the study. Diagnosis was based on bacterial used to test first the global null hypothesis of no differ-
culture, high plasma levels of C reactive protein, procal- ence between the four groups, followed by three group
citonin levels higher then 1 ng/ml, and fever. comparison and finally the pair-wise comparison in case
Patients with rheumatoid arthritis. Twenty-four patients the previous null hypothesis could be rejected. P values
with rheumatoid arthritis, diagnosed according to the have to be interpreted descriptively. All analyses were
American Rheumatism Association criteria [23], were performed with SAS, version 6.12.
also included in the study. The group was heterogenous
with regard to activity or severity of disease according to
RESULTSa house score. Most patients with active disease received
Polymorphonuclear neutrophils of healthy donors ex-low-dose corticoids.
pressed little or no MHC II antigens (median 0.95%, inter-Healthy individuals. For comparison, PMNs of healthy
quartile range 0.48 to 1.99%, MHC II-positive PMNs).individuals (N 5 54) of the same age and with the same
In patients with active Wegener’s granulomatosis, thesex distribution as the patients of groups A and B were
expression of MHC II was found on PMNs. In some pa-analyzed.
tients, up to 15% of the PMNs were positive for MHC II
Determination of surface expression on (Fig. 1).
polymorphonuclear neutrophils by cytofluorometry To assess whether MHC II expression on PMNs was
linked to disease activity, a prospective study with 58The respective surface molecules were detected by
patients with the diagnosis Wegener’s granulomatosisdouble labeling with fluorescein (FITC)-conjugated anti-
was performed. When entering the study, 16 patients hadbody to CD66b as marker for PMNs and phycoerythrin
active disease (BVAS of more than 1). Forty-two pa-(PE)-conjugated antibodies to MHC II (anti-DP, -DQ,
-DR). The antibodies were purchased from Dianova tients with known disease were in remission either under
Ha¨nsch et al: Expression of MHC II antigens on PMNs 1813
Fig. 1. Expression of MHC II or of CD64 on PMNs of patients with Wegener’s granulomatosis. By cytofluorometry using a FITC-labeled antibody
to CD66b as marker for PMNs and a PE-labeled antibody to HLA-DR, a shift of the PMN population toward higher fluorescence intensity was
noted with cells of a patients with active disease (upper right, B). PMNs of a healthy donor remain in the lower quadrant, indicating that PMNs
are positive for CD66b, but not for MHC II (A). The lower panels show data for CD64 expression on PMNs. A FITC-labeled antibody to CD66b
was used together with a PE-labeled anti-CD64. A patient with active disease is shown in (D), and a patient with inactive disease is shown in (C ).
immunosuppressive therapy (N 5 21) or without therapy tients showed low expression of MHC II on PMNs. The
others were negative (Fig. 2).(N 5 21). Of the 16 patients with active disease, 13
expressed MHC II on the peripheral PMNs (median All of the 16 patients who had active disease when
entering the study went into remission. Twelve remained6.5%; Fig. 2). Of the patients who entered the study
when under immunosuppressive therapy (BVAS 1 or 0), clinically inactive, but four developed a relapse, which
again was associated with the expression of MHC IIonly 2 of 21 had MHC II-positive PMNs. Of the patients
with inactive disease and no therapy (N 5 21), five pa- antigens on PMNs (Table 1).
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Fig. 2. Expression of MHC II antigens on
PMNs. The data obtained with PMNs of pa-
tients with Wegener’s granulomatosis, patients
with sepsis (N 5 24), and rheumatoid arthritis
(RA; N 5 24), and of healthy donors (N 5
54) are summarized as box charts. Patients
with active disease when entering the study
(N 5 16) showed higher MHC II expression
than patients with inactive disease under im-
munosuppressive therapy (N 5 21) or patients
with inactive disease and no therapy (N 5 21)
or the patients with sepsis or RA, respectively.
Table 1. MHC class II expression and expression of CD64 on PMN of patients with Wegener’s disease
Disease activity when entering the study
Inactive disease and Inactive disease and
Active disease immunosuppressive therapy no therapy
Total number of patients 16 21 21
MHC class II positive PMN (,3% of PMN)a 13/16 2/21 5/21
CD64 positive PMN (,10% of PMN)a 8/16 10/21 11/21
Positive ANCA/PR3 titer (.1:20)a 11/16 11/21 9/21
Patients developing relapse
Total number 4 6 (7)b 2
MHC class II positive PMN 4/4 5/6 (6/7)b 1/2
CD64 positive PMN (,10%) 0/4 3/6 (4/7)b 1/2
Rise in ANCA/PR titer (.1:20) 2/4 5/6 (5/7)b 0/2
a Analyzing the data of the healthy donors, the third quartile of the level of MHC class II expression was used as the threshold
b Including the patient with two relapses
Within the observation time (20 months), a majority 21 with no therapy), eight suffered a relapse, which in
six was associated with MHC II expression on PMNsof the patients came repeatedly to the hospital for a
routine check-up (6- to 8-week intervals) or when compli- (Table 1). One patient had two episodes of disease activ-
ity, both occurring concomitantly with enhanced MHCcations arose. At each time, disease activity and MHC II
expression were determined, allowing correlation of II expression (Fig. 3).
For statistical analysis, two situations were considered.these two parameters in the same patient.
The follow-up studies (in some patients up to 18 First, based on the clinical presentation when individuals
entered the study, four groups were formed: patientsmonths) showed that MHC II expression remained low
or was unmeasurable when the disease remained inactive. with active disease (N 5 16), patients with inactive dis-
ease and immunosuppressive therapy (N 5 21), and pa-Of the patients who had entered the study with inac-
tive disease (N 5 21 under immunosuppressive therapy; tients with inactive disease and no therapy (N 5 21),
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Fig. 3. A follow-up study of a patient with
Wegener’s granulomatosis. The patient en-
tered the study with inactive disease. He de-
veloped a relapse accompanied by a surface
expression of MHC II on PMNs and a rise in
ANCA titer. Under immunosuppressive ther-
apy, MHC II expression declined, as did the
ANCA titer. In December 1997, the patient
discontinued the immunosuppressive therapy.
He developed a second relapse, again associ-
ated with MHC II expression and a rise in
ANCA titer.
and healthy controls (N 5 54). Each patient was consid- PR3 antibody. Of the patients negative for MHC class
II (N 5 5), two had a high autoantibody titer. One hadered only once, namely, when entering the study. The
data obtained during the follow-up studies were disre- only a low level of ANCA (1:40), and two had no autoan-
tibodies at all. On the other hand, patients who nevergarded. Under these premises, MHC II expression was
statistically different in the four groups (P , 0.001) and had any ANCA were MHC II positive. In patients having
both autoantibody and MHC II, the respective levels didalso in the three-group comparison (largest P value 0.01).
By pair-wise comparison, MHC II expression of the pa- not correlate with each other; moreover, disease activity
measured as BVAS did not correlate with the autoanti-tients’ PMNs was different from MHC II expression of
the control group (largest P value 0.01), and MHC II body titer nor with the extent of MHC II expression.
Under immunosuppressive therapy, the portion of theexpression of patients with active disease differed mark-
edly from that of both groups of patients with inactive MHC II-positive PMNs decreased within days. The
MHC II reduction paralleled the reduction of CD25 ex-disease (P , 0.01). There was, however, no difference
between patients with inactive disease and immunosup- pression on peripheral T cells and, as expected, preceded
the decline of the ANCA titers (Fig. 4).pressive therapy and patients with inactive disease with-
out therapy and healthy controls (P 5 0.93). As a further parameter for leukocyte activation, the
absolute leukocyte count was considered. The medianIn the second analysis, whether or not a change in
disease activity coincided with a change in MHC II ex- values, 6.1 for patients with active disease, 6.7 for patients
with inactive disease and immunosuppressive therapy,pression in the same patient was calculated. In 14 of 19
events (74%, 95% CI, 0.49 to 0.91) the changes were and 5.95 for patients with inactive disease and no ther-
apy, did not differ. Moreover, there was no correlationsimultaneous.
Eleven of the 16 patients (69%) who at the beginning between leukocyte count and MHC II expression (r 5
0.31 for the group of patients with active disease).of the study presented with active disease had ANCA
(titers ranging from 1:40 to 1:640) and autoantibodies to As another indicator of PMN activation, the expres-
sion of CD64, the inducible high-affinity receptor forPR3 (ranging from 11.5 to 200), as had 7 of the 12 patients
with a relapse (75%; Table 1). MHC II expression, how- IgG (FcgRI) on PMNs, was measured in all patients as
well as in the healthy donors. PMNs of healthy donorsever, was not linked to the presence of ANCA or the
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Fig. 4. A follow-up study of a patients with
active Wegener’ granulomatosis. The patient
entered the study with active disease, MHC
II on PMNs, ANCA titer of 1:640 and 78%
of interleukin 2 receptor (CD25)-positive
T-cells. Under immunosuppressive therapy,
the number of MHC II-positive cells declined,
as did the ANCA titer and the percentage of
CD25-positive T cells.
either expressed no CD64 or very little CD64 on only a
low percentage of PMNs. In approximately 50% of the
patients with active Wegener’s disease, a high expression
of CD64 was seen in up to 80% of the PMNs (Fig. 1).
There was no difference between patients with active
disease and patients taking immunosuppressive therapy
or patients with inactive disease and no therapy (Fig. 5).
The expression of CD64 was not linked to the expres-
sion of MHC II. Of the patients with active disease and
MHC II-positive PMNs (N 5 24), only 11 were also
positive for CD64.
Major histocompatibility class II expression appears
not to be restricted to Wegener’s disease, but was also
seen in three of nine patients with active microscopic
polyangiitis. Also, PMNs of one patient with a newly
diagnosed Churg–Strauss syndrome showed a high ex-
pression of MHC II (27.9% MHC II-positive PMNs),
whereas two other patients with inactive Churg–Strauss
syndrome had PMNs negative for MHC II.
To determine whether or not MHC II expression was
Fig. 5. Expression of CD64 on PMN of patients with Wegener’s granu-also associated with other forms of inflammatory disease,
lomatosis (WG). PMNs of normal donors did not express CD64, butPMNs of patients with various systemic bacterial infec-
approximately 50% of patients with WG have CD64-positive PMN.
tions were tested for MHC II expression. Only 2 of 24 The median values obtained from patients with active disease or patients
with inactive disease were not different from each other but differedpatients had PMNs expressing a low amount of MHC II
from values obtained from healthy controls (P , 0.05).in 3 to 4% of the cells. The median value (1.17) was not
different from that seen for healthy controls (Fig. 2).
As an example of chronic inflammatory disease, pa-
tients with rheumatoid arthritis were tested. Here, a me-
our patients’ expression of CD25 as an indicator of T-celldian value of MHC II expression of 1.7% was deter-
activation, as well as the ratio of CD4-positive to CD8-mined. None of these patients had a MHC II expression
positive T cells. As already shown by others in almostabove 3% (Fig. 2).
all patients, whether with active or inactive disease, theAn ongoing study with patients suffering from lupus
proportion of CD8-positive cells was enhanced relativeerythematosus suggests that active disease is not corre-
to CD4-positive cells [7]. Moreover, CD25-positive Tlated to MHC II expression on PMNs.
cells ranging from 20 to 60% were found in all patients,Because recent publications point to the participation
of T cells in Wegener’s disease [7–9], we measured in again irrespective of disease activity (Table 2). In follow-
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Table 2. Analysis of peripheral T-cells of patients with lated PMNs of healthy donors [16]. Because activated T
Wegener’s granulomatosus
cells are found in vasculitic disease (unpublished obser-
CD4/CD8 % CD3/CD25 vations) [7], it is feasible that T-cell–derived cytokines
ratio positive cells such as interferon g induce expression of MHC II on
Patients with Wegener’s granulomatosis PMNs. The assumption is supported by the observation
Range 0.4–1.1 15%–68%
that MHC II expression decreases rapidly after immuno-Median 0.86 28%
Healthy donors suppressive therapy in parallel with the decline of CD25-
Range 1/9–2.4 0%–6% positive T cells. In that MHC II expression on PMNsMedian 2.02 2.3%
might be interpreted as an indicator of an ongoing im-
mune response, the interpretation is also in line with the
finding that renewed increase of MHC II coincided with
relapse.up studies, a decrease in CD25-positive T cells was noted
In approximately 50% of the patients with active dis-in those undergoing immunosuppressive therapy (Fig. 4).
ease, aside from MHC II, expression of CD64 was also
found on PMNs. Expression, however, was not restricted
DISCUSSION
to patients with active disease but was seen in 53% of
Constitutive MHC II expression is restricted to profes- patients with inactive disease. Although not ruling out
sional antigen-presenting cells, including dendritic cells, a role for the high-affinity Fc receptor in the course of
B cells, and cell of the monocyte/macrophage lineage. the disease, the expression of CD64 does not appear to
PMNs of healthy individuals normally do not express be a suitable marker for the diagnosis of active disease or
MHC II antigens. Expression, however, can be induced relapse. Apparently, the induction of CD64 expression is
by culturing the isolated cells in the presence of g inter- regulated independently of MHC II.
feron or granulocyte CSF [16]. We have now also found The consequences of MHC II expression on PMNs
MHC II-positive PMNs in vivo. PMNs of the peripheral are still a matter of speculation. So far, the only known
blood of patients with Wegener’s granulomatosis ex- function of MHC II molecules is the presentation of
pressed MHC II antigens as detected by cytofluorometry. antigenic peptides to T lymphocytes. Whether or not
MHC II expression was closely associated with active MHC II-positive PMN might fulfill such a function is
disease and declined rapidly under immunosuppressive under investigation. There are data showing that PMN
therapy. are able to function as accessory cells for staphylococcus
Thus, in addition to autoantibody titers [24–27], MHC enterotoxin-dependent T-cell proliferation [28], an ob-
II expression on PMNs might be a useful marker for
servation that is particularly interesting with regards to
active disease, particularly for the recognition of a re-
a possible involvement of staphylococcus enterotoxinslapse. MHC II expression of PMNs coincided more fre-
in the pathogenesis of vasculitis (abstract; Cohen Ter-quently with disease activity than the rise in PR3/ANCA
vaert et al, J Am Soc Nephrol 8:533A, 1997) [29].titers, most probably because of the rapid up-regulation
In conclusion, (a) MHC II expression on PMNs mightof MHC II and the rapid turnover of PMNs.
serve as a novel diagnostic marker for active vasculiticMajor histocompatibility class II expression is not up-
disease and appears to be suitable for monitoring theregulated in patients with severe bacterial infection, sug-
efficiency of immunotherapy. Extended long-term obser-gesting that MHC II expression is not imperatively
vations might tell whether MHC II expression precedeslinked to PMN activation as it occurs in infectious dis-
relapse or progression of the disease [2]. (b) MHC II onease. Thus, MHC II expression of PMNs might be helpful
PMNs may result from T-cell activation occurring into discriminate between relapses and acute infection.
active vasculitic disease, and points to an as yet unrecog-Furthermore, in patients suffering from rheumatoid ar-
nized function of PMNs within the afferent limb of thethritis, no MHC II expression was seen, indicating that
immune response.up-regulation of MHC II on PMNs is not necessarily
linked to all chronic inflammatory processes. Reprint requests to Gertrud Maria Ha¨nsch, Ph.D., Institut fu¨r Immu-
Although not yet studied systematically, MHC II ex- nologie, Ruprecht-Karls-Universita¨t Heidelberg, Im Neuenheimer Feld
305, 69120 Heidelberg, Germany.pression does not appear to be restricted to Wegener’s
Email: n50@ix.urz.uni-heidelberg.degranulomatosis, but also occurs in other forms of vasculi-
tis, including microscopic polyangiitis or Churg–Strauss
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